News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,782 Results
Type
Article (8018)
Company Profile (141)
Press Release (477892)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166745)
Career Advice (302)
Deals (25741)
Drug Delivery (7)
Drug Development (52868)
Employer Resources (14)
FDA (9760)
Job Trends (8568)
News (238206)
Policy (17894)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (490)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33156)
ALS (108)
Alzheimer's disease (985)
Antibody-drug conjugate (ADC) (284)
Approvals (10409)
Artificial intelligence (333)
ASCO (159)
Autoimmune disease (220)
Automation (30)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6958)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (1)
Bladder cancer (139)
Brain cancer (31)
Breast cancer (519)
Cancer (3759)
Cardiovascular disease (226)
Career advice (245)
Career pathing (1)
CAR-T (178)
CDC (1)
CDMO (15)
Celiac Disease (1)
Cell therapy (486)
Cervical cancer (35)
Clinical research (48041)
Collaboration (1279)
Commercialization (3)
Compensation (1533)
Complete response letters (34)
COVID-19 (762)
CRISPR (64)
C-suite (802)
Cystic fibrosis (87)
Data (5848)
Denatured (4)
Depression (106)
Dermatology (67)
Diabetes (354)
Diagnostics (4227)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (158)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73750)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88108)
Executive appointments (713)
FDA (12492)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (945)
Gene editing (126)
Generative AI (11)
Gene therapy (333)
GLP-1 (294)
Government (948)
Grass and pollen (2)
Guidances (281)
Healthcare (9367)
Hematology (94)
HIV (56)
Huntington's disease (23)
IgA nephropathy (68)
Immunology and inflammation (106)
Immuno-oncology (61)
Indications (162)
Infectious disease (955)
Inflammatory bowel disease (128)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (261)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1969)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (18)
Liver cancer (45)
Longevity (19)
Lung cancer (542)
Lymphoma (257)
Machine learning (29)
Management (3)
Manufacturing (565)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8679)
Medtech (8838)
Mergers & acquisitions (14412)
Metabolic disorders (726)
mRNA (62)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (227)
Neuropsychiatric disorders (40)
Neuroscience (1869)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (231)
Opinion (10)
Ovarian cancer (161)
Pain (177)
Pancreatic cancer (206)
Parkinson's disease (206)
Partnered (12)
Patents (497)
Patient recruitment (530)
Patient selection (2)
Peanut (32)
People (41360)
Peptides (2)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15519)
Phase 2 (21454)
Phase 3 (14465)
Pipeline (7690)
Policy (18)
Postmarket research (1570)
Preclinical (6553)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (195)
Rare diseases (588)
Real estate (3022)
Recruiting (6)
Regenerative medicine (2)
Regulatory (14960)
Reports (23)
Research institute (584)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (163)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Supply chain (51)
Vaccines (334)
Venture capital (17)
Weight loss (75)
Women's health (88)
Date
Last 7 days (284)
Last 30 days (1328)
Last 365 days (19012)
2026 (13626)
2025 (19238)
2024 (22990)
2023 (26539)
2022 (34594)
2021 (37162)
2020 (33482)
2019 (23266)
2018 (17468)
2017 (18767)
2016 (17919)
2015 (24263)
2014 (21676)
2013 (18135)
2012 (20221)
2011 (20427)
2010 (20333)
Location
Africa (227)
Alabama (77)
Alaska (2)
Arizona (310)
Arkansas (10)
Asia (17935)
Australia (2091)
California (12344)
Canada (3236)
China (544)
Colorado (496)
Connecticut (427)
Delaware (214)
Europe (24651)
Florida (1854)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (726)
India (51)
Indiana (323)
Iowa (16)
Japan (423)
Kansas (103)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1233)
Massachusetts (8100)
Michigan (314)
Minnesota (572)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (122)
New Hampshire (60)
New Jersey (2691)
New Mexico (12)
New York (2896)
North Carolina (1316)
North Dakota (4)
Northern California (6208)
Ohio (293)
Oklahoma (14)
Oregon (16)
Pennsylvania (2295)
Puerto Rico (21)
Rhode Island (30)
South America (402)
South Carolina (78)
South Dakota (1)
Southern California (5138)
Tennessee (125)
Texas (2004)
United States (40017)
Utah (372)
Vermont (1)
Virginia (159)
Washington D.C. (38)
Washington State (955)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,782 Results for "diasorin inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc.(Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit.
February 13, 2023
·
9 min read
Deals
Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit to Cytek for approximately USD 46.5 million.
February 28, 2023
·
6 min read
Policy
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
QIAGEN and DiaSorin announced that the U.S. Food and Drug Administration has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.
November 29, 2021
·
7 min read
Deals
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
DiaSorin S.p.A. (“DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (“Luminex"; NASDAQ: LMNX) for a price of USD 37.00 per share in an all-cash transaction.
April 12, 2021
·
18 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Press Releases
Allumiqs Solutions Inc. and Allumiqs Corporation
September 15, 2026
·
1 min read
Press Releases
Carlsmed, Inc. Announces Chief Operating Officer Appointment
September 8, 2026
·
2 min read
Press Releases
Glucotrack, Inc. Announces Reverse Stock Split
August 27, 2026
·
6 min read
Press Releases
PostEra’s Fertility programs acquired by EMD Serono, Inc.
September 9, 2026
·
2 min read
QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis
QIAGEN is responsible for product development and manufacturing, while DiaSorin is responsible for global commercialization of the new solution
April 21, 2021
·
10 min read
1 of 48,579
Next
